Kairos Pharma, LTD. financial data

Symbol
KAPA on NYSE
Location
2355 Westwood Blvd. #139, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 755 %
Return On Equity -79.2 %
Return On Assets -71.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.8M shares +62.1%
Common Stock, Shares, Outstanding 20.8M shares +62.1%
Common Stock, Value, Issued 21K USD +61.5%
Weighted Average Number of Shares Outstanding, Basic 20.2M shares +85.2%
Weighted Average Number of Shares Outstanding, Diluted 20.2M shares +85.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.77M USD +4243%
General and Administrative Expense 3.84M USD +124%
Operating Income (Loss) -5.61M USD -275%
Nonoperating Income (Expense) 546K USD
Net Income (Loss) Attributable to Parent -5.06M USD -33.5%
Earnings Per Share, Basic 0 USD/shares +30%
Earnings Per Share, Diluted 0 USD/shares +30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.58M USD
Assets, Current 6.66M USD +40.4%
Intangible Assets, Net (Excluding Goodwill) 102K USD -61.1%
Assets 8.07M USD +61.2%
Liabilities, Current 402K USD -76%
Liabilities 992K USD -67.4%
Retained Earnings (Accumulated Deficit) -12.9M USD -64.6%
Stockholders' Equity Attributable to Parent 7.66M USD +130%
Liabilities and Equity 8.07M USD +61.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -714K USD -2083%
Net Cash Provided by (Used in) Financing Activities 3.06M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 20.8M shares +62.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.34M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.58M USD +73.3%
Deferred Tax Assets, Valuation Allowance 841K USD -46.8%
Deferred Tax Assets, Gross 448K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.2M USD +39.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 20.5M USD +84.1%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 40K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%